Bentracimab Explained

Type:	mab
Mab Type:	Fab
Source:	u
Target:	Ticagrelor, AR-C124910XX (the active metabolite)^[1]
Routes Of Administration:	Intravenous infusion
Synonyms:	PB2452, MEDI2452
Atc Prefix:	None
Legal Status:	Investigational
Cas Number:	2260568-31-6
Pubchemsubstance:	405226665
Drugbank:	DB16659
Kegg:	D11799
Unii:	1TBM83QR9S
C:	2095
H:	3240
N:	560
O:	674
S:	12

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y₁₂ inhibitor and is sold under the brand name Brilinta among others).^[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.^[3] It is not commercially available.

See also

• Other reversal agents for antithrombotic drugs
  • Andexanet alfa
  • Ciraparantag
  • Vitamin K
  • Idarucizumab

Notes and References

1. Web site: Specialist Pharmacy Service: Bentracimab. 10 January 2021. National Health Service.
2. Web site: EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor . Cardiovascular News . 2021-01-29.
3. Makhdoum A, Dhingra NK, Kirubaharan A, Eikelboom R, Luc J, Dagher O, Bierer J, Cartier A, Vaillancourt O, Vo TX, Forgie K, Bisleri G, Yau TM, Verma S, Yanagawa B . 6 . Ticagrelor use and practice patterns among Canadian cardiac surgeons . Journal of Cardiac Surgery . 36 . 8 . 2793–2801 . August 2021 . 34028081 . 10.1111/jocs.15636 . free .